MCM7 and hepatocellular carcinoma: Given that only a few preclinical compounds inhibiting the MCM2–7 complex’s enzymatic activity and/or expression have been discovered48, and no FDA-approved drugs have been reported to target MCM complex, it is meaningful that we found ATO, approved in clinics, could target MCM7 in HCC.